Big data study tests if claims records can mimic Gold-Standard heart trials
NCT ID NCT07088718
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This completed study used health insurance claims data from over 44,000 people with type 2 diabetes and heart disease to see if it could predict results from a major clinical trial. Researchers compared two diabetes drugs, tirzepatide and dulaglutide, to see which better prevented heart attacks, strokes, or death. The goal was to learn when real-world data can be trusted to answer medical questions without running a full trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.